Skip to main content
Clinical Trials/NCT04595383
NCT04595383
Unknown
Not Applicable

Efficacy of an Electronic Communication Platform to Activate Diabetic Patients Treated With Insulin

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana0 sites106 target enrollmentOctober 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypoglycemia
Sponsor
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Enrollment
106
Primary Endpoint
Change from HbA1c level at 3 months
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to assess the efficacy of an electronic platform for doctor-patient communication in order to reduce severe and non-severe hypoglycemia events as well as inadvertent hypoglycemia events.

Detailed Description

This is an open randomized clinical trial without drugs. Patients with type 2 diabetes and treated with insulin will be included. Patients allocated in the intervention group will use the electronic platform as a communication channel with their health provider during the time between visits. The name of the platform is ti.care (https://ti.care/es) and it will be a complement of the control visits to resolve doubts through chats, email or video call. Health providers will answer the patient requests.

Registry
clinicaltrials.gov
Start Date
October 1, 2021
End Date
May 31, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Responsible Party
Principal Investigator
Principal Investigator

Domingo Orozco

Principal investigator

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Eligibility Criteria

Inclusion Criteria

  • Aged over 17 years
  • Patients with type 2 diabetes diagnosis
  • Patients who start insulin treatment or with intensification of treatment
  • Patients who sign informed consent

Exclusion Criteria

  • Patients with type 1 diabetes diagnosis
  • Life expectancy less than one year
  • Pregnancy
  • Patients with dementia
  • Patients with treatment different to insulin
  • Patients who, in the opinion of the researcher, cannot follow the recommendations of the self-care health education plan.

Outcomes

Primary Outcomes

Change from HbA1c level at 3 months

Time Frame: Baseline and at 3 months

Change from HbA1c level at 3 months

Change from postprandial blood glucose at 3 months

Time Frame: Baseline and at 3 months

Change from postprandial blood glucose at 3 months

Number of inadvertent hypoglycemia events

Time Frame: At 3 months

Number of inadvertent hypoglycemia events

Change from basal capillary blood glucose at 3 months

Time Frame: Baseline and at 3 months

Change from basal capillary blood glucose at 3 months

Change from nocturnal blood glucose at 3 months

Time Frame: Baseline and at 3 months

Change from nocturnal blood glucose at 3 months

Number of nocturnal hypoglycemia events

Time Frame: At 3 months

Number of nocturnal hypoglycemia events

Total hypoglycemia

Time Frame: At 3 months

Number of total hypoglycemia events

Similar Trials